Influence of Hemostatic Factors on Spontaneous Abortion

Deborah B. Nelson; Roberta B. Ness; Jeane Ann Grisso; Mary Cushman

doi:10.1055/s-2001-15503

American Journal of Perinatology, Table of Contents

Am J Perinatol 2001; 18(4): 195-202
DOI: 10.1055/s-2001-15503

ORIGINAL ARTICLES

Influence of Hemostatic Factors on Spontaneous Abortion

Deborah B. Nelson¹ , Roberta B. Ness¹ , Jeane Ann Grisso² , Mary Cushman³

¹Graduate School of Public Health, University of Pittsburgh, Pennsylvania
²Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
³Laboratory for Clinical Biochemistry Research, Department of Medicine, University of Vermont, Burlington, Vermont

Abstract

ABSTRACT

To assess the relationship between hemostatic factors and spontaneous abortion, 134 pregnant women presenting to the emergency department were recruited and followed through 22 weeks' gestation. Cases were women experiencing a spontaneous abortion and controls were women who maintained their pregnancy. Fibrinogen, factor VII antigen, activated protein C-sensitivity ratio (APC-SR), protein S, and plasmin-antiplasmin (PAP) were measured. Cases had lower mean levels of fibrinogen and factor VII antigen compared with controls (3.1 g/L vs. 3.7 g/L and 89% of normal vs. 109% of normal, respectively). Regression analyses found that women with fibrinogen levels below 3.0 g/L had a fivefold increased risk of spontaneous abortion (OR = 5.1, 95% CI: 1.8-14.4) and women with factor VII antigen levels below 94% of normal had a threefold increased risk of spontaneous abortion normal (OR = 3.3, 95% CI: 1.2-8.5). Similar mean levels of APC-SR, protein S, and PAP were found in the two groups.

KEYWORD

Fibrinogen - factor VII antigen - coagulation - spontaneous abortion

Full Text

References

REFERENCES

1 Kline J, Stein Z, Susser M. Conception to Birth: Epidemiology of Prenatal Development. New York: Oxford University Press; 1989
2 Hathaway W E, Bonnar J. Hemostatic Disorders of the Pregnant Woman and Newborn Infant. New York: Elsevier Science; 1987
3 Stirling Y, Woolf L, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy. Thromb Haemost . 1984; 52 176-182
4 Hellgren M. Hemostasis during pregnancy and puerperium. Haemostasis (suppl 4) . 1996; 26 (244-247)
5 Cabaniss C D, Cabaniss M L. Physiologic hematology in pregnancy. In: Kitay DZ, ed. Hematologic Problems in Pregnancy Oradell, NJ: Medical Economics Books; 1987
6 Allan A. Vaginal bleeding in early pregnancy. Practioner . 1994; 238 310-315
7 Salafia C, Maier D, Vogel C, Pezzullo J, Burns J, Silberman L. Placental and decidual histology in spontaneous abortion: detailed description and correlation with chromosome number. Obstet Gynecol . 1993; 82 295-303
8 Trauscht-Van Horn J J, Capeless E L, Easterling T R, Bovill E G. Pregnancy loss and thrombosis with protein C deficiency. Am J Obstet Gynecol . 1992; 167 968-972
9 Sanson B-J, Friederich P W, Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost . 1996; 75 387-388
10 Ridker P M, Miletich J P, Buring J E. Factor V leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med . 1998; 128 1000-1003
11 Brenner B, Mandel H, Lanir N. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol . 1997; 97 551-554
12 MacLean M A, Cuming G P, McCall F, Walker J J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriage. Br J Obstet Gynaecol . 1994; 101 103-106
13 Ginsberg J S, Brill-Edwards P, Johnston M. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood . 1992; 80 975-980
14 Rai R S, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod . 1995; 10 3301-3304
15 Ness R B, Grisso J A, Cifelli D. Cocaine use during early pregnancy increases the risk of spontaneous abortion. N Engl J Med . 1999; 340 333-339
16 Cushman M, Cornell E S, Howard P R, Bovill E G, Tracy R P. Laboratory methods and quality assurance in the cardiovascular health study. Clin Chem . 1995; 41 264-270
17 Hoffman C J, Miller R H, Hultin M B. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arteriosclerosis Thromb . 1992; 12 267-270
18 Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha-2-antiplasmin complex in human plasma: application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost . 1986; 56 124-127
19 Stewart D R, Overstreet J W, Nakajima S T, Lasley B L. Enhanced ovarian steroid secretion before implantation in early human pregnancy. J Clin Endocrinol Metab . 1993; 76 1470-1476
20 Stirling Y, Woolf L, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy. Thromb Haemost . 1984; 52 176-182
21 Grandone E, Margaglione M, Colaizzo D. Factor V leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost . 1997; 77 1052-1054
22 Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol . 1996; 92 489-490
23 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V leiden in 4047 men and women: implications for venous thromboembolism screening. J Am Med Assoc . 1997; 277 1305-1307